Literature DB >> 3877311

Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat.

N R Swerdlow, G F Koob.   

Abstract

Destruction of dopamine terminals within the nucleus accumbens (N.Acc.) with 6-hydroxydopamine blocked the locomotor activating properties of d-amphetamine, but not caffeine or corticotropin-releasing factor (CRF). Infusion of muscimol into the region of nucleus accumbens efferent terminals in the substantia innominata and lateral preoptic region (SI/LPO) blocked amphetamine-, but not caffeine- or CRF-stimulated locomotion. These muscimol infusions also blocked heroin-stimulated locomotion. These results suggest that amphetamine, acting through a process dependent on N.Acc. dopamine transmission, stimulates locomotion by decreasing GABAergic activity within this N.Acc.-SI/LPO projection; heroin, known to act through a process dependent on N.Acc. opiate receptor activation, also stimulates locomotion by decreasing GABAergic activity within the SI/LPO; caffeine and CRF produce their activation through different neural substrates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877311     DOI: 10.1016/0091-3057(85)90574-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Locomotor responses to benzodiazepines, barbiturates and ethanol in diazepam-sensitive (DS) and -resistant (DR) mice.

Authors:  T J Phillips; E J Gallaher
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Injection of Cocaine-Amphetamine Regulated Transcript (CART) peptide into the nucleus accumbens does not inhibit caffeine-induced locomotor activity: Implications for CART peptide mechanism.

Authors:  Martin O Job
Journal:  Pharmacol Biochem Behav       Date:  2016-05-07       Impact factor: 3.533

3.  Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens.

Authors:  N R Swerdlow; D L Braff; V L Masten; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior.

Authors:  B J Cole; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  The glutamatergic projection from the prefrontal cortex to the nucleus accumbens core is required for cocaine-induced decreases in ventral pallidal GABA.

Authors:  Mary M Torregrossa; X-C Tang; Peter W Kalivas
Journal:  Neurosci Lett       Date:  2008-04-10       Impact factor: 3.046

6.  Corticotropin releasing factor induces anxiogenic locomotion in trout and alters serotonergic and dopaminergic activity.

Authors:  Russ E Carpenter; Michael J Watt; Gina L Forster; Øyvind Øverli; Craig Bockholt; Kenneth J Renner; Cliff H Summers
Journal:  Horm Behav       Date:  2007-08-08       Impact factor: 3.587

7.  Central effects of corticotropin releasing factor (CRF): evidence for similar interactions with environmental novelty and with caffeine.

Authors:  D R Britton; E Indyk
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Motivational properties of ethanol in mice selectively bred for ethanol-induced locomotor differences.

Authors:  F O Risinger; D H Malott; L K Prather; D R Niehus; C L Cunningham
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

9.  A vapor exposure method for delivering heroin alters nociception, body temperature and spontaneous activity in female and male rats.

Authors:  Arnold Gutierrez; Kevin M Creehan; Michael A Taffe
Journal:  J Neurosci Methods       Date:  2020-10-30       Impact factor: 2.390

10.  Nucleus accumbens corticotropin-releasing factor increases cue-triggered motivation for sucrose reward: paradoxical positive incentive effects in stress?

Authors:  Susana Peciña; Jay Schulkin; Kent C Berridge
Journal:  BMC Biol       Date:  2006-04-13       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.